- Home
- CANF vs RDHL Comparison
CANF vs RDHL Comparison
Compare CANF & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CANF | RDHL |
|---|---|---|
| Founded | 1994 | 2009 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 5.4M |
| IPO Year | 2011 | 2012 |
Fundamental Metrics
Financial Performance| Metric | CANF | RDHL |
|---|---|---|
| Price | $3.45 | $1.01 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $50.00 | N/A |
| AVG Volume (30 Days) | ★ 938.6K | 54.5K |
| Earning Date | 03-26-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2,715,455.50 | $381.91 |
| Revenue Next Year | $101.06 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $0.71 |
| 52 Week High | $10.40 | $3.31 |
Technical Indicators
Market Signals| Indicator | CANF | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 56.46 | 59.95 |
| Support Level | $2.89 | $0.79 |
| Resistance Level | $4.74 | $1.07 |
| Average True Range (ATR) | 0.35 | 0.06 |
| MACD | 0.09 | 0.00 |
| Stochastic Oscillator | 52.80 | 71.42 |
Price Performance
Historical ComparisonAbout CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.